These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34365877)

  • 1. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
    Palominos PE; Lineburger IB; Xavier RM
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
    Alduraibi FK; Singh JA
    Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
    Atzeni F; Popa CD; Nucera V; Nurmohamed MT
    Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials.
    Wu J; Zhu Z; Yu Q; Ding C
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1113-1123. PubMed ID: 31738612
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
    Reddy V; Cohen S
    Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
    Russell MD; Stovin C; Alveyn E; Adeyemi O; Chan CKD; Patel V; Adas MA; Atzeni F; Ng KKH; Rutherford AI; Norton S; Cope AP; Galloway JB
    Ann Rheum Dis; 2023 Aug; 82(8):1059-1067. PubMed ID: 37247942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated to long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population.
    Sebastiani M; Zabotti A; Biasi B; Cacioppo S; Sandri G; Giovannini I; Manfredi A; Quartuccio L
    Clin Exp Rheumatol; 2024 Jul; 42(7):1416-1420. PubMed ID: 38530664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
    Kwon OC; Choi W; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
    Adv Rheumatol; 2024 Apr; 64(1):26. PubMed ID: 38622706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
    Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
    Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
    Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
    Singh JA
    BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
    Tokareva K; Reid P; Yang V; Liew D; Peterson AC; Baraff A; Giles J; Singh N
    Expert Rev Clin Immunol; 2023; 19(11):1385-1397. PubMed ID: 37596779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
    Krüger K
    Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
    Sonomoto K; Tanaka Y
    Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.